Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Biogen’s Alzheimer’s drug poses an existential question

  • Damian Garde

By Damian Garde June 6, 2018

Reprints
Beta-Amyloid Plaques
National Institute on Aging/NIH

So-called BACE drugs, biopharma’s next (and possibly doomed) hope for treating Alzheimer’s disease, have had a difficult run of form lately. First, two big trials from Merck came up short, and then another from Johnson & Johnson ran into damning safety problems.

And the latest data, on a BACE drug from Biogen, may only underline growing fears in Alzheimer’s research.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Tags

Newly available test strips can detect lethal ‘tranq’ in…
Newly available test strips can detect lethal ‘tranq’ in drug supply
Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
Bernie Sanders’ accidentally great drug pricing idea
Bernie Sanders’ accidentally great drug pricing idea
Pharmalittle: FDA proposes more rigorous cancer drug trials for…
Pharmalittle: FDA proposes more rigorous cancer drug trials for accelerated approval; insurers not covering obesity meds…
Under protest, FDA to convene advisory panel to review…
Under protest, FDA to convene advisory panel to review controversial cell therapy for ALS
Why the world’s smallest wheelchairs are going unused
Why the world’s smallest wheelchairs are going unused

Comments are closed.

Recommended Stories